Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

BioOutsource Opens New Facility in Cambridge, Massachusetts

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
First North American offices opened in response to surging demand for company’s bioanalytical and biosafety services.

BioOutsource Ltd. announced the opening of a new facility in Cambridge, Massachusetts, the company’s first in the United States. The company plans to draw on its unparalleled depth of experience in providing biosimilar characterization assays to its European customers, in providing similar services throughout North America. The announcement was made at the 2013 BIO International Convention, “the Global Event for Biotechnology,” in Chicago, Illinois.

“We have opened this new office, our first in the U.S., in response to  increasing demand from across the North American market for our market-leading BioAnalytical services, and particularly in the field of biological  biosimilar characterization,” commented BioOutsource CEO Gerry MacKay. “Our U.S. office will facilitate engagement with North American customers for our off-the-shelf  biosimilar biological characterization assays, for example for Humira, Enbrel, Rituxan, Herceptin, Remicade, and Avastin.”

The office will be located at the Cambridge Innovation Center, 1 Broadway, 14th Floor, Cambridge, Mass, 02142. The Cambridge Innovation Center is located on Kendall Square, adjacent to the Massachusetts Institute of Technology campus and home to a number of growing life sciences and venture capital firms.

“We are in the fortunate position to have been first-to-market in both Europe and the U.S. with our assays, and count Big Pharma as well as leading biotechnology as valued customers,” said Verna McErlane, PhD, BioOutsource Director of Sales & Business Development, BioAnalytical Division. “We look forward to being able to interact with them and provide our market-leading services, that much more readily, from our North American base of operations in Cambridge. Cambridge is, of course, part of greater Boston, which is now the number one cluster for early-stage biotechnology, and a growing center of operations for some of the world’s leading pharmaceutical firms, as well.”

Mr. MacKay concluded, “We see the North American market as an essential strategic element of our global expansion plans. We remain committed to not only growing our business in North America but in nurturing our relationships with our existing North American clients, as well. We invite all our customers and potential customers to stop by our new offices whenever you are in the Boston area.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Combo of 3 Antibiotics Can Kill Deadly Staph Infections
Three antibiotics that, individually, are not effective against a drug-resistant staph infection can kill the deadly pathogen when combined as a trio, according to new research.
Microbe Artwork Shows The Limits Of Antibiotics
An Oxford University research fellow has been creating art using bacteria found in the human gut and harvested from faecal samples.
Urine Excretion From Stem Cell-Derived Kidneys
Researchers report a strategy for enabling urine excretion from kidneys grown from stem cells.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos